OSL:BGBIO - Euronext Oslo - NO0013251173 - Common Stock - Currency: NOK
OSL:BGBIO (6/19/2025, 3:27:02 PM)
1.394
-0.03 (-1.97%)
The current stock price of BGBIO.OL is 1.394 NOK. In the past month the price decreased by -23.57%. In the past year, price decreased by -86.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 18.61 | 293.65B | ||
4AB.DE | ABBVIE INC | 17.98 | 283.33B | ||
AMG.DE | AMGEN INC | 13.95 | 135.29B | ||
GIS.DE | GILEAD SCIENCES INC | 14.08 | 117.83B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 99.95B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.92 | 49.56B | ||
ARGX.BR | ARGENX SE | 101.76 | 28.89B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.76B | ||
IDP.DE | BIOGEN INC | 8.05 | 16.21B | ||
1EXEL.MI | EXELIXIS INC | 18.83 | 9.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.71B | ||
0QF.DE | MODERNA INC | N/A | 8.48B |
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 15 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
BERGENBIO ASA
Mollendalsbakken 9
Bergen HORDALAND NO
Employees: 14
Phone: 4755961159
The current stock price of BGBIO.OL is 1.394 NOK. The price decreased by -1.97% in the last trading session.
The exchange symbol of BERGENBIO ASA is BGBIO and it is listed on the Euronext Oslo exchange.
BGBIO.OL stock is listed on the Euronext Oslo exchange.
7 analysts have analysed BGBIO.OL and the average price target is 5.1 NOK. This implies a price increase of 265.85% is expected in the next year compared to the current price of 1.394. Check the BERGENBIO ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BERGENBIO ASA (BGBIO.OL) has a market capitalization of 54.49M NOK. This makes BGBIO.OL a Micro Cap stock.
BERGENBIO ASA (BGBIO.OL) currently has 14 employees.
BERGENBIO ASA (BGBIO.OL) has a support level at 1.37 and a resistance level at 1.4. Check the full technical report for a detailed analysis of BGBIO.OL support and resistance levels.
The Revenue of BERGENBIO ASA (BGBIO.OL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BGBIO.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BGBIO.OL does not pay a dividend.
BERGENBIO ASA (BGBIO.OL) will report earnings on 2025-08-20.
BERGENBIO ASA (BGBIO.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).
ChartMill assigns a fundamental rating of 2 / 10 to BGBIO.OL. The financial health of BGBIO.OL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months BGBIO.OL reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -125.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -89.4% | ||
ROE | -113.51% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 40% to BGBIO.OL. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 17.6% and a revenue growth -100% for BGBIO.OL